Abstract
There are relatively few studies on the disposition properties of quinidine. We have studied in 10 normal subjects conventional quinidine sulfate and a slow-release quinidine bisulfate. Single and repetitive doses were given; blood and urine concentrations were measured by the method of Cramer and Isaakson.5 After a single dose of two tablets of quinidine sulfate (400 mg), the average peak concentration was 2.13 ± 0.22 μg/ml (±SEM); following two tablets of the slow-release form, the average peak concentration was 1.17 ± 0.12 μg/ml T-max was approximately 2 hr with quinidine sulfate and 4 hr with quinidine bisulfate. One fourth of both forms of the drug was recovered in the urine. Total body clearance was 0.36 Llkg ·hr and renal clearance was 117 ± 22 ml/min for both. With multiple dosing the serum quinidine concentration was higher than these predicted from the results of the single-dose study. Based on the mean estimates of quinidine half-life of 6 hr, a rapid method for achieving steady-state levels of quinidine would be to give an initial dose twice that of the maintenance dose. With the slow-release product if an equivalent dose was given every 12 hr, the mean steady-state quinidine serum concentration would be approximately the same.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 566-575 |
| Number of pages | 10 |
| Journal | Clinical Pharmacology and Therapeutics |
| Volume | 19 |
| Issue number | 5 PART 1 |
| State | Published - May 1976 |
| Externally published | Yes |
Fingerprint
ASJC Scopus subject areas
- Pharmacology
Cite this
Disposition kinetics of two oral forms of quinidine. / Mahon, W. A.; Mayersohn, Michael; Inaba, T.
In: Clinical Pharmacology and Therapeutics, Vol. 19, No. 5 PART 1, 05.1976, p. 566-575.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Disposition kinetics of two oral forms of quinidine
AU - Mahon, W. A.
AU - Mayersohn, Michael
AU - Inaba, T.
PY - 1976/5
Y1 - 1976/5
N2 - There are relatively few studies on the disposition properties of quinidine. We have studied in 10 normal subjects conventional quinidine sulfate and a slow-release quinidine bisulfate. Single and repetitive doses were given; blood and urine concentrations were measured by the method of Cramer and Isaakson.5 After a single dose of two tablets of quinidine sulfate (400 mg), the average peak concentration was 2.13 ± 0.22 μg/ml (±SEM); following two tablets of the slow-release form, the average peak concentration was 1.17 ± 0.12 μg/ml T-max was approximately 2 hr with quinidine sulfate and 4 hr with quinidine bisulfate. One fourth of both forms of the drug was recovered in the urine. Total body clearance was 0.36 Llkg ·hr and renal clearance was 117 ± 22 ml/min for both. With multiple dosing the serum quinidine concentration was higher than these predicted from the results of the single-dose study. Based on the mean estimates of quinidine half-life of 6 hr, a rapid method for achieving steady-state levels of quinidine would be to give an initial dose twice that of the maintenance dose. With the slow-release product if an equivalent dose was given every 12 hr, the mean steady-state quinidine serum concentration would be approximately the same.
AB - There are relatively few studies on the disposition properties of quinidine. We have studied in 10 normal subjects conventional quinidine sulfate and a slow-release quinidine bisulfate. Single and repetitive doses were given; blood and urine concentrations were measured by the method of Cramer and Isaakson.5 After a single dose of two tablets of quinidine sulfate (400 mg), the average peak concentration was 2.13 ± 0.22 μg/ml (±SEM); following two tablets of the slow-release form, the average peak concentration was 1.17 ± 0.12 μg/ml T-max was approximately 2 hr with quinidine sulfate and 4 hr with quinidine bisulfate. One fourth of both forms of the drug was recovered in the urine. Total body clearance was 0.36 Llkg ·hr and renal clearance was 117 ± 22 ml/min for both. With multiple dosing the serum quinidine concentration was higher than these predicted from the results of the single-dose study. Based on the mean estimates of quinidine half-life of 6 hr, a rapid method for achieving steady-state levels of quinidine would be to give an initial dose twice that of the maintenance dose. With the slow-release product if an equivalent dose was given every 12 hr, the mean steady-state quinidine serum concentration would be approximately the same.
UR - http://www.scopus.com/inward/record.url?scp=0017080173&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0017080173&partnerID=8YFLogxK
M3 - Article
C2 - 1277713
AN - SCOPUS:0017080173
VL - 19
SP - 566
EP - 575
JO - Clinical Pharmacology and Therapeutics
JF - Clinical Pharmacology and Therapeutics
SN - 0009-9236
IS - 5 PART 1
ER -